Skip to content
Lantus(insulin glargine)
Basaglar, Lantus, Optisulin, Rezvoglar, Semglee, Soliqua, Suliqua, Toujeo (insulin glargine) is a protein pharmaceutical. Insulin glargine was first approved as Lantus on 2000-04-20. It is used to treat hyperglycemia, type 1 diabetes mellitus, and type 2 diabetes mellitus in the USA. It has been approved in Europe to treat diabetes mellitus and type 2 diabetes mellitus.
Download report
Favorite
Top Prescription Drugs
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
immune system diseasesD007154
Trade Name
FDA
EMA
Basaglar, Lantus, Rezvoglar, Semglee, Toujeo
Combinations
Soliqua
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin glargine
Tradename
Proper name
Company
Number
Date
Products
Basaglarinsulin glargineEli LillyN-205692 RX2015-12-16
2 products
Toujeoinsulin glargineSanofiN-206538 RX2015-02-25
2 products
Lantusinsulin glargineSanofiN-21081 RX2000-04-20
2 products
Show 2 discontinued
Insulin glargine
+
Lixisenatide
Tradename
Proper name
Company
Number
Date
Products
Soliqua 100/33insulin glargine and lixisenatideSanofiN-208673 RX2016-11-21
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
basaglar basaglar Biologic Licensing Application2021-02-22
lantus solostarBiologic Licensing Application2023-02-06
rezvoglar kwikpenBiologic Licensing Application2023-05-02
semgleeBiologic Licensing Application2021-07-13
soliqua 100/33Biologic Licensing Application2021-08-04
toujeoBiologic Licensing Application2023-04-27
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
hyperglycemiaHP_0003074D006943R73.9
type 1 diabetes mellitusEFO_0001359D003922E10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
Expiration
Code
insulin glargine, Semglee, Mylan Pharmaceuticals Inc.
11/15/2022Interchangeable excl.
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
A10: Drugs used in diabetes
A10A: Insulins and analogues
A10AE: Insulins and analogues for injection, long-acting
A10AE04: Insulin glargine
A10AE54: Insulin glargine and lixisenatide
HCPCS
No data
Clinical
Clinical Trials
540 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11251213515314339
Type 1 diabetes mellitusD003922EFO_0001359E10397372710118
Diabetes mellitusD003920EFO_0000400E08-E1335612531
HyperglycemiaD006943HP_0003074R73.91411218
Diabetic ketoacidosisD016883EFO_10008971348
Chronic renal insufficiencyD051436N181113
Non-alcoholic fatty liver diseaseD065626EFO_0003095K75.8133
Coronary artery diseaseD003324I25.133
HypoglycemiaD007003HP_0001943E16.2213
Cardiovascular diseasesD002318EFO_0000319I98112
Show 11 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.9213
Prediabetic stateD011236EFO_1001121R73.0322
LeukemiaD007938C9522
LymphomaD008223C85.911
Varicose ulcerD01464711
Wound healingD014945GO_004206011
StrokeD020521EFO_0000712I63.911
Myocardial infarctionD009203EFO_0000612I2111
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients1515
Diabetic retinopathyD003930EFO_000377011
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetic neuropathiesD003929EFO_100078311
Kidney transplantationD01603011
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameINSULIN GLARGINE
INNinsulin glargine
Description
Insulin glargine recombinant
Classification
Protein
Drug class
Image (chem structure or protein)INSULIN GLARGINE
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB4IYD, 4IYF, 5VIZ
CAS-ID160337-95-1
RxCUI274783
ChEMBL IDCHEMBL1201497
ChEBI ID
PubChem CID
DrugBankDB00047
UNII ID2ZM8CX04RZ (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Basaglar - Eli Lilly
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Lantus - Sanofi
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Toujeo - Sanofi
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 7,741 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
12,835 adverse events reported
View more details